IgY pharmacokinetics in rabbits: Implications for IgY use as antivenoms

Díaz, Patricia; Malavé, Caridad; Zerpa, Noraida; Vázquez, Hilda; D’Suze, Gina; Montero, Yuyibeth; Castillo, Cecilia; Alagón, Alejandro; Sevcik, Carlos

doi:10.1016/j.toxicon.2014.07.021

Cited by 15 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, IgY does not bind mammalian complement factors and Fc-receptors making its use in mammals relatively uncomplicated (Inoue et al, 2015;Larsson et al, 1991). As expected, if IgY was provided parenterally to mammals a host immune response towards IgY was observed (Diaz et al, 2014). However, such problems have not been reported when administering IgY enterally (Michael et al, 2010).…”

Section: Egg Yolk Immunoglobulinsmentioning

confidence: 86%

Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems

Hedegaard

Heegaard

2016

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

show abstract

Section: Egg Yolk Immunoglobulinsmentioning

confidence: 86%

Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems

Hedegaard

Heegaard

2016

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

show abstract

“…The previous reports by Klemperer in 1893 and Guimarães et al, in 2009 have stated that, IgY treatment could reduce the risk of tetanus toxin (Klemperer, 1893;Guimarães et al, 2009), we also experienced similar neutralization effects of IgY (data not shown). As far as antivenoms produced based on chicken IgY have been tried in humans (Kiem, 2000;Diaz et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

“…However, antitoxin or antivenoms are mostly produced in hyper immunized mammals (Theakston and Warrell, 1991). Recently, numerous studies are supporting the immunotherapeutic use of avian IgY antibodies (Diaz et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

“…are scanty. Only limited numbers of studies (with preliminary findings) have been reported on IgY against snake venoms and some other toxins (Polson et al, 1980;Diaz et al, 2014). Thus, it is indispensable to understand the consequences after i.v.…”

Section: Introductionmentioning

confidence: 99%

“…The previous study have investigated the pharmacokinetics of antivenoms IgY in rabbits after i.v. administration, IgY PK lacks the fast initial decay, last less time in the body, reaches a smaller volume of distribution in steady state (Diaz et al, 2014). However, it would be still interesting to compare the pharmacokinetic characteristics of IgY and IgG, and to evaluate the feasibility of IgY in parenteral administration with regard to its pharmacokinetic and safety concerns.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparative study on Pharmacokinetic Profiles of Chicken IgY to Horse IgG in Rabbits

Zhou

Wang

Gao

et al. 2018

J Hellenic Vet Med Soc

View full text Add to dashboard Cite

ABSTRACT. Chicken IgY antibody has been extensively reported for various applications as an alternative to mammalian IgG. To evaluated the pharmacokinetics profile of chicken IgY in comparison with horse IgG. Chicken IgY antibody was prepared by immunizing the white leghorn chicken with tetanus toxoid (TT) and then extracted anti-TT-IgY from immune egg yolks by PEG-6000 extraction. The titer of anti-TT-IgY was determined by ELISA in order to select the hyper immune eggs for further extraction. Rabbits were injected with 300 μg/kg of Chicken IgY and horse IgG by intravenous (i.v.) and intramuscular (i.m.) administrations. Then, the concentrations of IgY and IgG in rabbit serum were determined using indirect ELISA. Pharmacokinetic parameters were estimated using non-compartmental analysis. IgY can reach higher concentration (C max = 4.54 mg/L after i.m. injection) within shorter time (T max = 0.12 h after i.m. injection) than IgG (C max = 3.99 ng/mL after i.m. injection; T max =0.11 h after i.m. injection), while the IgY lifespan (T 1/2 =26.98 h and 31.98 h after i.v. and i.m. administration, respectively) in the body was comparable with IgG (T 1/2 =27.94 h and 29.58 h after i.v. and i.m. administration, respectively). IgY might be a promising choice as an alternative to mammalian sourced antibodies.

show abstract

Translational Toxinology: Venom to Antivenom

Keyler¹

2017

Toxinology

View full text Add to dashboard Cite

A great natural diversity exists across animal taxa and species that produce venom, and although venoms are primarily used in the acquisition of prey and secondarily for defense, it is their adverse effects on humans that have driven scientific and medical research. The spectrum of venom-producing organisms and the venom components and toxins across organism species is highly variable. Venom components function in concert and selectively in their actions producing pathophysiological effects for subduing prey. In contrast, when non-prey species such as humans are encountered, the biting or stinging as a result of a defensive or fear response may result in envenomation. Following envenomation a myriad of venom-/toxin-induced adverse and toxicological insults to various physiological systems may result. What creatures are venomous, how they envenomate, their venom composition, how their venom components/toxins work mechanistically, and the pathophysiological effects of venom in envenomated humans led to the quest for remedies and antidotes. Prominently, among therapeutic advancements was the development of passive antisera therapy in the late1800s for cobra envenomation (Calmette 1894). Today's formulations of snake venom immunotherapies (antivenom) are relatively unchanged with respect to general antibody structure and mechanism of action. However, recent technological advances in antibody preparation, purification, and product formulation and combined venomic and antivenomic technologies are leading to novel, refined toxin-targeted antivenoms (Calvete et al. 2009). Toxinology has been translational over time, across biological systems, across scientific disciplines, and technologically, leading to our improved understanding of venom-producing animals, venoms, and the design and development of more efficacious antivenoms.

show abstract

IgY pharmacokinetics in rabbits: Implications for IgY use as antivenoms

Cited by 15 publications

References 50 publications

Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems

Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems

Comparative study on Pharmacokinetic Profiles of Chicken IgY to Horse IgG in Rabbits

Translational Toxinology: Venom to Antivenom

Contact Info

Product

Resources

About